Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 59 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Spironolactone Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

NCT00879060
View directory record Official record
Conditions
Myocardial Fibrosis, Hypertrophic Cardiomyopathy
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial

NCT02285920
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Spironolactone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 30, 2026, 7:24 PM EDT
Recruiting Phase 1 Interventional

Spironolactone in Alcohol Use Disorder (SAUD)

NCT05807139
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Placebo, Spironolactone
Other · Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 7:24 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Does Spironolactone Normalize Sleep-wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism?

NCT04723862
View directory record Official record
Conditions
Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 3 Interventional

Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

NCT03048825
View directory record Official record
Conditions
ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction
Interventions
Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo
Drug · Device
Lead sponsor
Population Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
7,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Bakersfield, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 4 Interventional Results available

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

NCT04676646
View directory record Official record
Conditions
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Interventions
Sodium zirconium cyclosilicate, Placebo, Spironolactone
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 30, 2026, 7:24 PM EDT
Recruiting Phase 1Phase 2 Interventional

HEART: Pilot Randomized Controlled Trial

NCT07483177
View directory record Official record
Conditions
Thoracic Aortic Aneurysm
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 30, 2026, 7:24 PM EDT
Recruiting Phase 3 Interventional

Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

NCT02901184
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Spironolactone, Standard care
Drug · Other
Lead sponsor
Uppsala University
Other
Eligibility
50 Years to 99 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
38
States / cities
Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 30, 2026, 7:24 PM EDT
Terminated Phase 1 Interventional Results available

A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

NCT01488877
View directory record Official record
Conditions
Type 2 Diabetic Nephropathy
Interventions
PF-03882845, Spironolactone, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
6
States / cities
Chula Vista, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment

NCT01897727
View directory record Official record
Conditions
Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
Interventions
Spironolactone, BP medication uptitration
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 4 Interventional

Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia

NCT04522739
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Learn How the Body Processes Spironolactone and Hydrochlorothiazide Film Coated Tablets Manufactured at Two Sites: Viatris and Neolpharma

NCT06205407
View directory record Official record
Conditions
Healthy Participants
Interventions
Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Viatris, Spironolactone/Hydrochlorothiazide (25 mg/25 mg) film coated tablets from Neolpharma.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Sep 30, 2026, 7:24 PM EDT
Withdrawn Phase 4 Interventional

Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients

NCT04205136
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 30, 2026, 7:24 PM EDT
Not yet recruiting Phase 2 Interventional

LOw DosE Spironolactone, chlorThAlidone oR Combination in CKD Trial

NCT07645300
View directory record Official record
Conditions
Hypertension Treated With Antihypertensive Drugs, Chronic Kidney Disease, 3B and 4
Interventions
phase 2A Chlorthalidone, phase 2A Spironolactone, phase 2A Chlorthalidone + Spironolactone, phase 2B Chlorthalidone LD + Spironolactone LD
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 90 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Sep 30, 2026, 7:24 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne

NCT04582383
View directory record Official record
Conditions
Acne
Interventions
Spironolactone, Doxycycline Hyclate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
16 Years to 40 Years · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
18
States / cities
Fort Smith, Arkansas • San Francisco, California • Sherman Oaks, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional

Hemodynamic Effects of Spironolactone in Patients With Heart Failure

NCT00860340
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Spironolactone
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
21 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 30, 2026, 7:24 PM EDT
Not listed Phase 2 Interventional

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

NCT05222191
View directory record Official record
Conditions
Renal Insufficiency, Chronic Hypertension
Interventions
Spironolactone, Chlorthalidone, Placebo
Drug
Lead sponsor
Indiana Institute for Medical Research
Other
Eligibility
19 Years to 110 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Sep 30, 2026, 7:24 PM EDT
Not listed Phase 2Phase 3 Interventional

Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease

NCT01721655
View directory record Official record
Conditions
Chronic Lung Disease, Bronchopulmonary Dysplasia
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
West Virginia University Healthcare
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 30, 2026, 7:24 PM EDT
Withdrawn Phase 4 Interventional

Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease

NCT00548912
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
Spironolactone
Drug
Lead sponsor
Dawnmarie DeFazio
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Not applicable Interventional Results available

Spironolactone in Patients With Single Ventricle Heart

NCT00211081
View directory record Official record
Conditions
Congenital Disorders
Interventions
Spironolactone (drug)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 30, 2026, 7:24 PM EDT
Withdrawn Phase 3 Interventional

A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease

NCT07223502
View directory record Official record
Conditions
Hypertension (HTN)
Interventions
Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 30, 2026, 7:24 PM EDT
Not listed Phase 4 Interventional

Effects of Spironolactone on Collagen Metabolism in Patients With Pulmonary Arterial Hypertension

NCT01468571
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Sep 30, 2026, 7:24 PM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

NCT03502031
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2
Interventions
Renin-Angiotensin (RAAS) alone, Renin-Angiotensin (RAAS) blockers in combination with Spironolactone
Drug
Lead sponsor
James A. Tumlin, MD
Other
Eligibility
75 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Lawrenceville, Georgia • Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Sep 30, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Spironolactone in Adult Congenital Heart Disease

NCT01069510
View directory record Official record
Conditions
Congenital Heart Disease, Heart Failure, Endomyocardial Fibrosis
Interventions
Spironolactone 25mg, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 30, 2026, 7:24 PM EDT